EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

Andriy A Gorbenko iD, Titiaan E Post iD, Pamela K Strugala iD, Erica S Klaassen iD, Linda E Klumpers iD, Saco J de Visser iD, Cristina Sempio iD, Jost Klawitter iD, Jules A A C Heuberger iD, Geert J Groeneveld iD

British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1595-1606

DOI: 10.1002/bcp.70415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 15.12.2025. Verfasst von Andriy A Gorbenko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Amitriptyline, Cannabidiol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol, two commonly used analgesics.

Methods

This was an open‐label, fixed‐sequence, 2‐way crossover study in 13 healthy participants. On Day 1, 25 mg amitriptyline and 50 mg tramadol were co‐administered orally in a fasted condition, followed by a 7‐day washout period. On Day 8, 30 mg CBD was administered orally 1 h prior to amitriptyline and tramadol. Pharmacokinetic sampling was performed for CBD, amitriptyline, tramadol and their respective active metabolites nortriptyline and O‐desmethyltramadol for up to 24 h post‐dose. The areas under the curve (AUCs) were compared between visits using a mixed effects model.

Results

Twelve participants (4M/8F) completed the study; one participant (M) dropped out for personal reasons. CBD significantly increased the AUC 0‐24h (least square means [LSM] ratio 1.13, 95% CI: 1.01, 1.26, p = 0.033) and the C max (LSM ratio 1.17, 95% CI: 1.01, 1.36, p = 0.041 ) of amitriptyline. CBD did not significantly change the AUC 0‐24h and C max of nortriptyline and tramadol, and the C max of O‐desmethyltramadol.

Conclusions

A single dose of 30 mg CBD significantly influenced the metabolism of amitriptyline in healthy volunteers. In patients, CBD‐induced drug interactions may be more pronounced in chronic dosing and dependent upon prandial status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmitriptylineCannabidiolHumansDrug InteractionsMaleCross-Over StudiesAdultFemaleTramadolYoung AdultArea Under CurveMiddle AgedAnalgesics, OpioidHealthy VolunteersNortriptyline

Stichwörter der Autor:innen

CBDCYP2C19DDIamitriptylinecannabidiolinteractiontramadol

Substanzen

AmitriptylineCannabidiolTramadolAnalgesics, OpioidNortriptylineO-demethyltramadol

Autor:innen und Institutionen

  • Centre for Human Drug Research, Leiden, The Netherlands.
  • Leiden University Medical Centre, Leiden, The Netherlands.
  • Verdient Science, LLC., Denver, CO, USA.
  • Tomori Pharmacology, Inc., Denver, CO, USA.
  • Larner College of Medicine, University of Vermont, Burlington, VT, USA.
  • Centre for Future Affordable and Sustainable Therapy development (FAST), the Hague, the Netherlands.

ORCID-Profile: Andriy A Gorbenko, Titiaan E Post, Pamela K Strugala, Erica S Klaassen, Linda E Klumpers, Saco J de Visser, Cristina Sempio, Jost Klawitter, Jules A A C Heuberger, Geert J Groeneveld

Förderung

  • ZonMw

Zitieren

APA

Gorbenko, A. A., Post, T. E., Strugala, P. K., Klaassen, E. S., Klumpers, L. E., de Visser, S. J., Sempio, C., Klawitter, J., Heuberger, J. A. A. C., & Groeneveld, G. J. (2026). Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology, 92(6), 1595-1606. https://doi.org/10.1002/bcp.70415

Vancouver

Gorbenko AA, Post TE, Strugala PK, Klaassen ES, Klumpers LE, de Visser SJ, et al. Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology. 2026;92(6):1595-1606. doi:10.1002/bcp.70415

BibTeX
@article{Gorbenko2026,
  author = {Gorbenko, Andriy A and Post, Titiaan E and Strugala, Pamela K and Klaassen, Erica S and Klumpers, Linda E and de Visser, Saco J and Sempio, Cristina and Klawitter, Jost and Heuberger, Jules A A C and Groeneveld, Geert J},
  title = {Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {6},
  pages = {1595--1606},
  doi = {10.1002/bcp.70415}
}
Kostenlos starten →